Influence of age, frailty and liver function on the pharmacokinetics of brofaromine

European Journal of Clinical Pharmacology

Volumn 49, Issue 5, 1996, Pages 387-391

  Zeeh, J ^a   Fuchs, L ^b   Bergmann, W ^a   Antonin, K H ^b   Degel, F ^c   Bieck, P ^b   Platt, D ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Human Pharmacology Institute   (Germany)

^c KLINIKUM NÜRNBERG   (Germany)

Author keywords

Elderly; Geriatrics; Liver function tests; Pharmacokinetics

Indexed keywords

BROFAROMINE; CAFFEINE;

ABSORPTION; ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; LIVER FUNCTION TEST; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030064921     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00203783     Document Type: Article

References (27)

1. Bieck P, Firkusny L, Schick C, et al (1989) Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. Clin Pharmacol Ther 45:260-269
2. Schiwy W, Heath W, Delini-Stula A (1989) Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine. Results of dose-finding trials in depressed patients. J Neural Transm 28:S33-S44
3. Robinson DS, Davis JM, Nies A, et al (1972) Aging and monoamineoxidase levels. Lancet 1:290-291
4. Robinson DS (1984) Age-related factors affecting antidepressant drug metabolism and clinical response. In: Nancy K (ed). Geriatric psychopharmacology. Elsevier North Holland, New York
5. Nolan L, O'Malley K (1992) Adverse effects of antidepressants in the elderly. Drugs Aging 2:450-458
6. Hengen N, Jedrychowski M, Hoffmann E (1984) Pharmacokinetics of CGP 11 305 A in man after acute and prolonged oral treatment. In: Tipton KF, Dostert P, Strolin Benedetti M (eds) Monoamine oxidase and disease. Academic Press, London, pp 185-191
7. Woodhouse K, Wynne H (1988) Age-related changes in liver size and hepatic blood flow. The influence on drug metabolism in the elderly. Clin Pharmacokinet 15:287-294
8. Colli A, Buccino G, Cocciolo M, Parravicini R, Scaltrini G (1988) Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis. Clin Pharmacol Ther 44:642-649
9. Schnegg M, Lauterburg B (1986) Quantitative liver function in the eldely assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 3: 164-171
10. Zeeh J, Lange H, Bosch J, et al (1988) Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. Gastroenterology 95:749-759
11. Renner E, Wietholtz H, Huguenin P, Arnaud M, Preisig R (1984) Caffeine: a model compound for measuring liver function. Hepatology 4:38-46
12. Applegate W, Blass J, Williams T (1990) Instruments for the functional assessment of older patients. N Engl J Med 322:1207-1214
13. Qureshi N, Hodkinson H (1974) Evaluation of a ten-question mental test in the institutionalized elderly. Age Ageing 3: 152-157
14. Schneider W, Keller B, Degen P (1988) Determination of a new monoamine oxidase inhibitor brofaromine in biological material by gas chromatography with electron-capture detection. J Chromatogr 488:275-282
15. Wahlländer A, Mohr S, Paumgartner G (1990) Assessment of hepatic function. Comparison of caffeine clearance in serum and saliva during the day and at night. J Hepatol 10:129-137
16. Bergmeyer HU, Gruber W, Gutmann I (1974) D-Sorbit. In: Bergmeyer HU (ed) Methoden der enzymatischen Analyse. Verlag Chemie, Weinheim, pp 1368-1375
17. Antonin KH, Kucher K, Fuchs L, Bieck PR, Schmidt E (1992) Investigation of dose proportionality and absolute bioavailability of brofaromine in healthy volunteers. Clin Neuropharmacol 15:430B.
18. Blanchard J, Sawers S (1983) The absolute bioavailability of caffeine in man. Eur J Clin Pharmacol 24:93-98
19. Cheng W, Murphy T, Smith M, Cooksley W, Halliday J, Powell L (1990) Dose-dependent pharmacokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 47:516-524
20. Pritchard F, Bryson J, Kernodle A, Benedetti T, Powell J (1992) Age and gender effects on odansetron pharmacokinetics: Evaluation of healthy aged volunteers. Clin Pharmacol Ther 51:51-55
21. Crooks J, O'Malley K, Stevenson I (1976) Pharmacokinetics in the elderly. Clin Pharmacokinet 1:280-296
22. Powell JR, Cate EW (1986) Induction and inhibition of metabolism. In: Evans WE, Schentag JJ, Jusko WJ (eds) Applied pharmacokinetics: principles of therapeutic drug monitoring. Applied Therapeutics, Spokane, Washington, pp 139-186
23. Wynne H, Cope L, Herd B, Rawlins M, James O, Woodhouse K (1990) The association of age and frailty with paracetamol conjugation in man. Age Ageing 19:419-424
24. Schellens J, van der Wart J, Danhof M, van der Velde E, Breimer D (1988) Relationship between the metabolism of antipyrine, hexobarbitone and theophylline in man as assessed by a "cocktail" approach. Br J Clin Pharmacol 26:373-384
25. Kalow W, Tang B (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 50:508-519
26. Tang-Liu D, Williams R, Riegelman S (1983) Disposition of caffeine and its metabolites in man. J Pharmacol Exp Ther 224: 180-185
27. Kalow W, Tang B (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44-48